A Phase 1/2a Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy And VRE-Colonized Subjects
Latest Information Update: 01 Nov 2023
At a glance
- Drugs Bacteriophage therapeutic Ferring Pharmaceuticals/Intralytix (Primary)
- Indications Vancomycin-resistant enterococcal infections
- Focus Adverse reactions; First in man
- Sponsors Intralytix
Most Recent Events
- 26 Oct 2023 Status changed from not yet recruiting to recruiting.
- 27 Jan 2023 Status changed from planning to not yet recruiting.
- 30 Nov 2022 New trial record